|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our previous study showed that the protocadherin 17 (<i>PCDH17</i>) gene was frequently methylated and functioned as a tumor suppressor in CRC.
|
31815010 |
2019 |
|
Colorectal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our previous study showed that the protocadherin 17 (<i>PCDH17</i>) gene was frequently methylated and functioned as a tumor suppressor in CRC.
|
31815010 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
Biomarker
|
disease |
BEFREE |
PCDH17 increases the sensitivity of colorectal cancer to 5-fluorouracil treatment by inducing apoptosis and autophagic cell death.
|
31815010 |
2019 |
|
Malignant neoplasm of urinary bladder
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
The p53 mutation, the expression of p53 and PCDH17 were significantly associated with survival from bladder cancer.
|
31772653 |
2019 |
|
Bladder Neoplasm
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
The p53 mutation, the expression of p53 and PCDH17 were significantly associated with survival from bladder cancer.
|
31772653 |
2019 |
|
Carcinoma of bladder
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
The p53 mutation, the expression of p53 and PCDH17 were significantly associated with survival from bladder cancer.
|
31772653 |
2019 |
|
Carcinoma of urinary bladder, invasive
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, p53 mutation and low expression of PCDH17 were significantly associated with muscle-invasive bladder cancer.
|
31772653 |
2019 |
|
Schizophrenia
|
0.410 |
GeneticVariation
|
disease |
GWASCAT |
Pleiotropic Meta-Analysis of Cognition, Education, and Schizophrenia Differentiates Roles of Early Neurodevelopmental and Adult Synaptic Pathways.
|
31374203 |
2019 |
|
Intelligence
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Pleiotropic Meta-Analysis of Cognition, Education, and Schizophrenia Differentiates Roles of Early Neurodevelopmental and Adult Synaptic Pathways.
|
31374203 |
2019 |
|
Cardiomyopathy, Familial Idiopathic
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
<b>Conclusion</b>: Our study suggests that DCRF can act as a competing endogenous RNA to increase PCDH17 expression by sponging miR-551b-5p, thus contributing to increased cardiomyocyte autophagy in DCM.
|
31285779 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Moreover, low PCDH17 expression predicted worse overall survival (OS) in four independent cohorts as well as in the molecularly defined subgroups of AML patients.
|
30922328 |
2019 |
|
Acute Undifferentiated Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We identified protocadherin17 (PCDH17) and demonstrated that it was significantly down-regulated and hypermethylated in LSCs compared with HSCs.
|
30922328 |
2019 |
|
Undifferentiated leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We identified protocadherin17 (PCDH17) and demonstrated that it was significantly down-regulated and hypermethylated in LSCs compared with HSCs.
|
30922328 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Protocadherin 17 is a tumor suppressor and is frequently methylated in nasopharyngeal carcinoma.
|
30863170 |
2019 |
|
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
In addition, no statistical significance was found in cell proliferation, apoptosis, invasion and migration between Control group and miR-196b mimics+PCDH-17 group.
|
30454973 |
2019 |
|
Laryngeal Squamous Cell Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
And low expression of miR-196b and high expression of PCDH-17 contributed to an increase in the 5-year-survival rate of LSCC patients.
|
30454973 |
2019 |
|
Gastritis, Atrophic
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In the protein expression analysis, PCDH17 expression was inversely associated with gastric lesions; the OR [95% confidence interval (CI)] was 0.49 (0.26-0.95) for chronic atrophic gastritis (CAG), 0.31 (0.15-0.63) for intestinal metaplasia, and 0.38 (0.19-0.75) for indefinite dysplasia and dysplasia, compared with superficial gastritis.
|
30213786 |
2018 |
|
Superficial gastritis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In the protein expression analysis, PCDH17 expression was inversely associated with gastric lesions; the OR [95% confidence interval (CI)] was 0.49 (0.26-0.95) for chronic atrophic gastritis (CAG), 0.31 (0.15-0.63) for intestinal metaplasia, and 0.38 (0.19-0.75) for indefinite dysplasia and dysplasia, compared with superficial gastritis.
|
30213786 |
2018 |
|
Intestinal metaplasia
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
In the protein expression analysis, PCDH17 expression was inversely associated with gastric lesions; the OR [95% confidence interval (CI)] was 0.49 (0.26-0.95) for chronic atrophic gastritis (CAG), 0.31 (0.15-0.63) for intestinal metaplasia, and 0.38 (0.19-0.75) for indefinite dysplasia and dysplasia, compared with superficial gastritis.
|
30213786 |
2018 |
|
Malignant neoplasm of nasopharynx
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Aberrant promoter methylation reduced the expression of protocadherin 17 in nasopharyngeal cancer.
|
30165032 |
2019 |
|
Cancer of Nasopharynx
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Aberrant promoter methylation reduced the expression of protocadherin 17 in nasopharyngeal cancer.
|
30165032 |
2019 |
|
Nasopharyngeal carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Aberrant hypermethylation in the promoter might be the explanation of PCDH17 downregulated in PCDH17 and promoted the development of NPC.
|
30165032 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Subsequent gene expression analysis of PCDH17 revealed decreased expression in all of the tumor samples in comparison to the control ones.
|
29991130 |
2018 |
|
Ovarian Carcinoma
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
PCDH17 methylation was detected in almost 70% of HGSOC patients without any methylation in the group of control samples and was found both in the late stage tumors as well as in the early stage ones.
|
29991130 |
2018 |